Understanding how certain cancer treatments cause cell death
A Pathway for Necrotic Cell Death
This study is looking at how two cancer-fighting drugs, BHPI and ErSO, cause cancer cells to die and how they can help the immune system do its job better, with the goal of finding new and better treatments for cancers like breast and ovarian cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Urbana-Champaign NIH-funded |
| Lab location | 1 site (Champaign, United States) |
| Project ID | NIH-10894785 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind necrotic cell death induced by specific anticancer drugs, BHPI and ErSO, which target estrogen receptor α. By studying how these drugs activate immune responses and lead to cell death, the research aims to enhance drug development and cancer immunotherapy. The team utilizes advanced techniques, including CRISPR screens, to identify key proteins involved in this process, which could lead to more effective treatments for various cancers, including breast and ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with estrogen receptor-positive breast cancer, ovarian cancer, or other cancers resistant to current therapies.
Not a fit: Patients with cancers that do not express estrogen receptors or those who are not eligible for experimental treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the body's immune response to fight tumors.
How similar studies have performed: Other research has shown promise in utilizing necrotic cell death mechanisms for cancer treatment, indicating that this approach could be a valuable addition to existing therapies.
Where this research is happening
Champaign, United States
- University of Illinois at Urbana-Champaign — Champaign, United States (Active)
Researchers
- Principal investigator: Shapiro, David J — University of Illinois at Urbana-Champaign
- Study coordinator: Shapiro, David J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.